Apellis seeks a Senior Manager Internal Communications to develop and execute communication programs that strengthen company culture drive employee engagement and connect our team. This individual will manage company-wide internal communication channels and events to ensure consistent clear and inspiring communication across the organizationand will also lead our annual Volunteer Day.
Reporting to the Vice President Communications this person will collaborate closely with colleagues across Communications HR and other functions to design and deliver programs that bring Apellis culture and values to life.
At Apellis our passion for science and our commitment to patients drive everything we doand this role helps bring that purpose to life for our employees every day. Were looking for someone with an entrepreneurial spirit exceptional writing and project management skills and the ability to thrive in a fast-paced environment.
Key Responsibilities
Key Qualifications
Skills & Abilities
Benefits and Perks:
Base salary for this role will consider multiple factors including but not limited to candidate qualifications relevant expertise specialized skills and industry experience in complement-targeted therapies.
The targeted base salary range for this position is $152000.00 - $227000.00 per year. This range represents the base salary only and reflects Apellis commitment to competitive compensation within the biopharmaceutical industry. The final salary offered may vary based on individual qualifications business needs and current market conditions. per year. This range represents the base salary only and reflects Apellis commitment to competitive compensation within the biopharmaceutical industry. The final salary offered may vary based on individual qualifications business needs and current market conditions.
Apellis offers a comprehensive benefits package including a 401(k) plan with company match inclusive family building benefits flexible time off summer and winter shutdowns paid family leave disability and life insurance and more! Visithttps:// learn more.
Company Background:
Apellis Pharmaceuticals Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway we believe we have only begun to unlock the potential of targeting C3 across many serious diseases.
For more information please visit follow us onTwitterandLinkedIn
EEO Statement:
Apellis is an equal opportunity employer and complies with all applicable federal state and local fair employment practices laws. Apellis strictly prohibits and does not tolerate discrimination against employees applicants or any other covered persons because of race color religion creed national origin or ancestry ethnicity sex (including pregnancy) gender (including gender nonconformity and status as a transgender or transsexual individual) age physical or mental disability citizenship past current or prospective service in the uniformed services genetic information marital status AIDS/HIV status smoker/nonsmoker and occupational pneumoconiosis or any other characteristic protected under applicable federal state or local law.
For San Francisco postings: Pursuant to the San Francisco Fair Chance Ordinance we will consider for employment qualified applicants with arrest and conviction records.
Other Duties:
Please note this job description is not designed to cover or contain a comprehensive listing of activities duties or responsibilities that are required of the employee for this job. Duties responsibilities and activities may change at any time with or without notice.
Required Experience:
Senior Manager
Apellis is a global biopharmaceutical company that develops life-changing therapies. By pioneering targeted C3 therapies, we aim to treat diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, and nephrology.